Cathie Wood & ARK Invest Portfolio Shifts: Major Sales in BLDE, ROKU, and Continued Focus on Biotech
ARK Invest (Cathie Wood) saw significant changes this quarter with major reductions in holdings like BLDE and ROKU offset by notable additions to Intellia Therapeutics (NTLA). The portfolio remains heavily weighted towards Technology and Healthcare.
ARK Invest, led by renowned investor Cathie Wood, continues its distinctive investment approach focused on disruptive innovation. As of June 30th, 2026, the fund's total assets under management reached $12.88 billion.
The portfolio allocation remains heavily concentrated in Technology and Healthcare sectors combined at nearly 56% ($7.49B). Consumer Cyclical holds a significant portion of the rest with 12.89%, followed by Communication Services (9.18%) and Financial Services (7.45%). Unknown sector allocation accounts for about $653M or 5.07%. ARK Invest's detailed holdings are available at their profile.
This quarter saw substantial shifts in Cathie Wood's portfolio, with significant reductions across several positions:
- Strata Critical Medical (BLDE): Shares decreased by -63.37%, a notable reduction for this position.
- Roku Inc (ROKU): Experienced an outsized decline of -84.4% in its portfolio allocation, one of the most significant sell-offs reported.
- Baidu Inc (BIDU): Also saw a substantial reduction (-73.05%) despite being listed as "significant sell" by ARK Invest.
Conversely, Cathie Wood's portfolio showed strong buying interest in certain companies:
- Intellia Therapeutics (NTLA): Portfolio allocation increased significantly to 1.85%, suggesting renewed confidence.
- Prime Medicine Inc (PRME): Allocation jumped by +33.65% this quarter, indicating strong interest in the biotech space.
The portfolio also saw adjustments and exits across other sectors:
- Pacific Biosciences (PACB): Reduced its allocation by -17.9% this quarter, though it remains a position held by ARK Invest.
ARK Invest's holdings continue to reflect Cathie Wood's focus on technology and healthcare themes, albeit with adjustments based on performance and strategic shifts. The fund maintains positions in established tech leaders like Tesla (TSLA) and Amazon (AMZN), alongside emerging sectors represented by companies such as Twst Bioscience (TWST) and 10X Genomics (TXG).